GGrantIndex
Sort

35,931 grants matching parkinsons

Aging and Parkinson's Disease: Models of Therapeutics and Neurologic Comorbidity

$1,142,463
Timothy J. Collier · Michigan State University · P50 · FY2012 · NS

Molecular &Behavioral Effects of Low Level Mn Exposure

$1,142,463
Johns Hopkins University · R01 · FY2004 · ES

A Clinical Trial of AAV2-BDNF Gene Therapy in Alzheimer's Disease

$1,141,927
Mark H Tuszynski · University Of California, San Diego · R01 · FY2022 · AG

Dissecting Oligogenic Biomarkers in Ashkenazi Jews with Parkinson Disease

$1,141,563
Rachel Saunders-Pullman · Icahn School Of Medicine At Mount Sinai · U01 · FY2019 · NS

Role of molecular chaperones in protein folding diseases

$1,140,600
Lois Greene · National Heart, Lung, And Blood Institute · ZIA · FY2019 · HL

Mechanisms of axon guidance during development

$1,140,478
Edward Giniger · National Institute Of Neurological Disorders And Stroke · ZIA · FY2013 · NS

Molecular Genetics Of Scrapie Pathogenesis

$1,139,579
Suzette Alise Priola · National Institute Of Allergy And Infectious Diseases · ZIA · FY2024 · AI

Deciphering innate immune signaling mechanisms in glial cells linking lifetime environmental exposures to neuroinflammation, protein aggregation and neurodegeneration in Parkinsons disease

$1,139,354
Ronald B Tjalkens · Colorado State University · R35 · FY2023 · ES

LONGTERM CHANGES IN THE MAMMALIAN BRAIN

$1,139,036
University Of California San Francisco · P50 · FY2000 · MH

Molecular Genetics Of Early Eye Development

$1,139,032
Stanislav I Tomarev · National Eye Institute · ZIA · FY2024 · EY

Detection of Prions

$1,137,875
Byron Caughey · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI

Parkinson's Disease Data Organizing Center

$1,137,270
Roger M Kurlan · University Of Rochester · U01 · FY2010 · NS

Phase III Trial of Minocycline in ALS:I-Clinical Center

$1,136,760
Columbia University Health Sciences · R01 · FY2004 · NS

Human Embryonic Stem Cells: Characterization and Dopaminergic Differentiation

$1,136,747
William Freed · National Institute On Drug Abuse · ZIA · FY2012 · DA

Innovating next generation technologies to define mechanisms of neurodegenerative disease and devise therapeutic strategies

$1,136,484
Aaron D. Gitler · Stanford University · R35 · FY2025 · NS

Molecular Genetics Of Scrapie Pathogenesis

$1,135,879
Suzette Alise Priola · National Institute Of Allergy And Infectious Diseases · ZIA · FY2018 · AI

UCLA CENTER FOR THE STUDY OF PARKINSON'S DISEASE

$1,135,852
University Of California Los Angeles · P50 · FY2003 · NS

A consortium effort to translate therapies for neurological diseases via an ex vivo organotypic platform

$1,135,383
Shawn Hingtgen · Univ Of North Carolina Chapel Hill · U01 · FY2023 · TR

Assessment of Candidate Loci in Neurological diseases

$1,135,220
Andrew Singleton · National Institute On Aging · ZIA · FY2021 · AG

DBS-Expert Pro: Automated Deep Brain Stimulation Programming Using Functional Mapping

$1,134,607
Dustin Allen Heldman · Great Lakes Neurotechnologies · R44 · FY2025 · NS

Subthalamic and corticosubthalamic coding of speech production

$1,134,330
Robert Mark Richardson · University Of Pittsburgh At Pittsburgh · U01 · FY2018 · NS

MITOCHONDRIAL ETIOLOGIES OF PARKINSON'S DISEASE

$1,134,015
University Of Virginia Charlottesville · P50 · FY2002 · NS

FAMILIAL PARKINSON'S DISEASE: CLUES TO PATHOGENESIS

$1,133,503
Brigham And Women'S Hospital · P50 · FY2004 · NS

Peripheral Tissue Biomarker for Premortem Diagnosis of Lewy Body Dementia

$1,133,032
Shu G Chen · Case Western Reserve University · R01 · FY2020 · NS

Innovating Yeast and Human Genetics Approaches to Define Mechanisms of Neurodegenerative Disease

$1,132,610
Aaron D. Gitler · Stanford University · R35 · FY2020 · NS